Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study-Reference-Cited by-同舟云学术

Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study

Published:2021-03-07 Issue:8 Volume:62 Page:1920-1929
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Xu Weilai¹²³,Ye Li¹²³,Mei Chen¹²³,Zhou Xin-ping¹²³,Ren Yanling¹²³,Ma Liya¹²³,Ye Xinnong¹³,Lu Chenxi²,Jin Jie¹³,Tong Hong-yan¹²³

Affiliation:

1. Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China

2. Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China

3. Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1891230

Reference29 articles.

1. Decitabine improves patient outcomes in myelodysplastic syndromes

2. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

3. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

4. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

5. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia;Frontiers in Cellular and Infection Microbiology;2022-11-30